Skip to main content
Top

Open Access 03-02-2025 | Cannabinoid | Original Article

Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey

Authors: Michael Savio, Hugh Kearney, Eric J. Downer

Published in: Irish Journal of Medical Science (1971 -)

Login to get access

Abstract

Background

Advancements continue to be made in the development of medicines containing components of the Cannabis sativa L. plant. Consultants can prescribe specific cannabis-based products for a restricted set of indications in Ireland, with neurologists being at the forefront of therapy. Much debate on the therapeutic potential/efficacy of such cannabis-based products exists.

Aim

The objective of this study was to conduct a national survey to determine the perspectives/views of Irish neurologists regarding the use of cannabis-based medicines.

Methods

An online anonymous survey was conducted to capture the perspectives and experiences of neurologists in Ireland regarding cannabis-based therapeutics.

Results

Thirty-four neurologists completed the survey in full, with study participants rating their knowledge of cannabis-based medicines as average. Data presented herein indicate that there is a need for educational programmes on the cannabinoid system and cannabinoid-based medicines, and the findings indicate that neurologists are interested in the use of cannabinoid-based medicines in their practice. Study participants were more divided with regard to the clarity of the process for accessing cannabis-based medicines, and the consensus is that the application process is unclear. Approximately one-third of participants have made an application to access medicinal cannabis-based products on behalf of a patient.

Conclusions

Data presented herein indicates that the majority of neurologists surveyed are aware of the current systems in place to access cannabis-based products for medicinal use in Ireland and that some engagement with these systems has taken place. A key finding is that educational programmes on the cannabinoid system and cannabis-based medicines are required.
Literature
1.
go back to reference Devinsky O and others (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378(20):1888–1897CrossRefPubMed Devinsky O and others (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378(20):1888–1897CrossRefPubMed
2.
go back to reference Devinsky O and others (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376(21):2011–2020CrossRefPubMed Devinsky O and others (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376(21):2011–2020CrossRefPubMed
3.
go back to reference Rekand T (2014) THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 71(Suppl 1):4–9CrossRefPubMed Rekand T (2014) THC:CBD spray and MS spasticity symptoms: data from latest studies. Eur Neurol 71(Suppl 1):4–9CrossRefPubMed
4.
go back to reference Hanus LO and others (2016) Phytocannabinoids: a unified critical inventory. Nat Prod Rep 33(12):1357–1392CrossRefPubMed Hanus LO and others (2016) Phytocannabinoids: a unified critical inventory. Nat Prod Rep 33(12):1357–1392CrossRefPubMed
5.
go back to reference Flachenecker P, Henze T, Zettl UK (2014) Nabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71(5–6):271–279CrossRefPubMed Flachenecker P, Henze T, Zettl UK (2014) Nabiximols (THC/CBD oromucosal spray, Sativex(R)) in clinical practice–results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol 71(5–6):271–279CrossRefPubMed
6.
go back to reference Stott CG and others (2013) A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 69(5):1135–1147CrossRefPubMed Stott CG and others (2013) A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol 69(5):1135–1147CrossRefPubMed
7.
go back to reference Badowski ME, Yanful PK (2018) Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag 14:643–651CrossRefPubMedPubMedCentral Badowski ME, Yanful PK (2018) Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Ther Clin Risk Manag 14:643–651CrossRefPubMedPubMedCentral
8.
go back to reference Berlach DM, Shir Y, Ware MA (2006) Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 7(1):25–29CrossRefPubMed Berlach DM, Shir Y, Ware MA (2006) Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med 7(1):25–29CrossRefPubMed
10.
go back to reference Pisanti S, Bifulco M (2019) Medical cannabis: a plurimillennial history of an evergreen. J Cell Physiol 234(6):8342–8351CrossRefPubMed Pisanti S, Bifulco M (2019) Medical cannabis: a plurimillennial history of an evergreen. J Cell Physiol 234(6):8342–8351CrossRefPubMed
11.
go back to reference Joshi N, Onaivi ES (2019) Endocannabinoid system components: overview and tissue distribution. Adv Exp Med Biol 1162:1–12CrossRefPubMed Joshi N, Onaivi ES (2019) Endocannabinoid system components: overview and tissue distribution. Adv Exp Med Biol 1162:1–12CrossRefPubMed
16.
go back to reference Elliott J and others (2020) Neurologists’ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: a qualitative interview study. Seizure 78:118–126CrossRefPubMed Elliott J and others (2020) Neurologists’ perspectives on medical cannabis for pediatric drug-resistant epilepsy in Canada: a qualitative interview study. Seizure 78:118–126CrossRefPubMed
18.
go back to reference Gardiner KM and others (2019) Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - a systematic review. PLoS ONE 14(5):e0216556CrossRefPubMedPubMedCentral Gardiner KM and others (2019) Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - a systematic review. PLoS ONE 14(5):e0216556CrossRefPubMedPubMedCentral
19.
go back to reference Van Hout MC and others (2017) Irish General Practitioner (GP) perspectives toward decriminalisation, legalisation and cannabis for therapeutic purposes (CTP). Int J Ment Heal Addict 15(3):670–683CrossRef Van Hout MC and others (2017) Irish General Practitioner (GP) perspectives toward decriminalisation, legalisation and cannabis for therapeutic purposes (CTP). Int J Ment Heal Addict 15(3):670–683CrossRef
20.
go back to reference Kondrad E, Reid A (2013) Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med 26(1):52–60CrossRefPubMed Kondrad E, Reid A (2013) Colorado family physicians’ attitudes toward medical marijuana. J Am Board Fam Med 26(1):52–60CrossRefPubMed
21.
go back to reference Griffith ST and others (2024) Cannabis use in Parkinson’s disease: patient access to medical cannabis and physician perspective on product safety. Neurotoxicology 103:198–205CrossRefPubMed Griffith ST and others (2024) Cannabis use in Parkinson’s disease: patient access to medical cannabis and physician perspective on product safety. Neurotoxicology 103:198–205CrossRefPubMed
22.
go back to reference Bega D and others (2017) Medicinal cannabis for Parkinson’s disease: practices, beliefs, and attitudes among providers at National Parkinson Foundation Centers of Excellence. Mov Disord Clin Pract 4(1):90–95CrossRefPubMed Bega D and others (2017) Medicinal cannabis for Parkinson’s disease: practices, beliefs, and attitudes among providers at National Parkinson Foundation Centers of Excellence. Mov Disord Clin Pract 4(1):90–95CrossRefPubMed
23.
go back to reference Lipman AG (2017) Medical cannabis for pain: anecdote or evidence. J Pain Palliat Care Pharmacother 31(2):96–97CrossRefPubMed Lipman AG (2017) Medical cannabis for pain: anecdote or evidence. J Pain Palliat Care Pharmacother 31(2):96–97CrossRefPubMed
25.
go back to reference Ronne ST and others (2021) Physicians’ experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review. BMC Fam Pract 22(1):212CrossRefPubMedPubMedCentral Ronne ST and others (2021) Physicians’ experiences, attitudes, and beliefs towards medical cannabis: a systematic literature review. BMC Fam Pract 22(1):212CrossRefPubMedPubMedCentral
26.
go back to reference Abuhasira R, Shbiro L, Landschaft Y (2018) Medical use of cannabis and cannabinoids containing products - regulations in Europe and North America. Eur J Intern Med 49:2–6CrossRefPubMed Abuhasira R, Shbiro L, Landschaft Y (2018) Medical use of cannabis and cannabinoids containing products - regulations in Europe and North America. Eur J Intern Med 49:2–6CrossRefPubMed
27.
go back to reference McGregor IS and others (2020) Access to cannabidiol without a prescription: a cross-country comparison and analysis. Int J Drug Policy 85:102935CrossRefPubMed McGregor IS and others (2020) Access to cannabidiol without a prescription: a cross-country comparison and analysis. Int J Drug Policy 85:102935CrossRefPubMed
28.
go back to reference Lipnik-Stangelj M, Razinger B (2020) A regulatory take on cannabis and cannabinoids for medicinal use in the European Union. Arh Hig Rada Toksikol 71(1):12–18PubMedPubMedCentral Lipnik-Stangelj M, Razinger B (2020) A regulatory take on cannabis and cannabinoids for medicinal use in the European Union. Arh Hig Rada Toksikol 71(1):12–18PubMedPubMedCentral
29.
go back to reference Hundertmark M and others (2024) Individual application patterns of cannabis-based medicines in Germany - descriptive evaluation of a patient survey and discussion from a forensic perspective. Forensic Sci Int 367:112352CrossRefPubMed Hundertmark M and others (2024) Individual application patterns of cannabis-based medicines in Germany - descriptive evaluation of a patient survey and discussion from a forensic perspective. Forensic Sci Int 367:112352CrossRefPubMed
30.
go back to reference Case P (2020) The NICE guideline on medicinal cannabis: keeping Pandora’s box shut tight? Med Law Rev 28(2):401–411CrossRefPubMed Case P (2020) The NICE guideline on medicinal cannabis: keeping Pandora’s box shut tight? Med Law Rev 28(2):401–411CrossRefPubMed
31.
go back to reference Olsson F and others (2023) An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Rev Clin Pharmacol 16(3):257–266CrossRefPubMed Olsson F and others (2023) An observational study of safety and clinical outcome measures across patient groups in the United Kingdom Medical Cannabis Registry. Expert Rev Clin Pharmacol 16(3):257–266CrossRefPubMed
32.
go back to reference Erridge S, Troup L, Sodergren MH (2024) Illicit cannabis use to self-treat chronic health conditions in the United Kingdom: cross-sectional study. JMIR Public Health Surveill 10:e57595CrossRefPubMedPubMedCentral Erridge S, Troup L, Sodergren MH (2024) Illicit cannabis use to self-treat chronic health conditions in the United Kingdom: cross-sectional study. JMIR Public Health Surveill 10:e57595CrossRefPubMedPubMedCentral
33.
go back to reference Ablin JN, Elkayam O, Fitzcharles MA (2016) Attitudes of Israeli rheumatologists to the use of medical cannabis as therapy for rheumatic disorders. Rambam Maimonides Med J 7(2):e0012CrossRefPubMedPubMedCentral Ablin JN, Elkayam O, Fitzcharles MA (2016) Attitudes of Israeli rheumatologists to the use of medical cannabis as therapy for rheumatic disorders. Rambam Maimonides Med J 7(2):e0012CrossRefPubMedPubMedCentral
34.
go back to reference Ebert T and others (2015) Assessment of Israeli physicians’ knowledge, experience and attitudes towards medical cannabis: a pilot study. Isr Med Assoc J 17(7):437–441PubMed Ebert T and others (2015) Assessment of Israeli physicians’ knowledge, experience and attitudes towards medical cannabis: a pilot study. Isr Med Assoc J 17(7):437–441PubMed
35.
go back to reference Hordowicz M and others (2021) Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review. Drug Alcohol Depend 221:108652CrossRefPubMed Hordowicz M and others (2021) Knowledge, attitudes, and prescribing patterns of cannabis and cannabinoid-containing medicines among European healthcare workers: a systematic literature review. Drug Alcohol Depend 221:108652CrossRefPubMed
36.
go back to reference Arnfinsen JL, Kisa A (2021) Assessment of Norwegian physicians’ knowledge, experience and attitudes towards medical cannabis. Drugs-Education Prevention and Policy 28(2):165–171CrossRef Arnfinsen JL, Kisa A (2021) Assessment of Norwegian physicians’ knowledge, experience and attitudes towards medical cannabis. Drugs-Education Prevention and Policy 28(2):165–171CrossRef
Metadata
Title
Neurologists’ perspectives of cannabis-based medicines: results from an all-Ireland survey
Authors
Michael Savio
Hugh Kearney
Eric J. Downer
Publication date
03-02-2025
Publisher
Springer International Publishing
Keyword
Cannabinoid
Published in
Irish Journal of Medical Science (1971 -)
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-025-03880-0

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more